Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 75%
filed 2026-08-17
EX-99.1
This is an announcement of an upcoming earnings release for the 2026 June quarter and interim financial results, scheduled for August 28, 2026. While the actual financial results have not yet been disclosed, the announcement itself signals a material periodic financial event. The company explicitly states it "plans to release its 2026 June quarter and interim financial results" and is scheduling a management earnings conference call to discuss those results, which is the standard disclosure pattern for earnings announcements. However, confidence is moderate (0.75) rather than high because this is technically an announcement *of* an earnings release rather than the release itself—the actual results will be furnished separately on August 28.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-17
Item 7.01
The disclosure announces NOAA's publication of a Notice of Intent to prepare an Environmental Impact Statement for TMC USA's deep seabed polymetallic nodule exploration license application under the Deep Seabed Hard Mineral Resources Act. This represents a material regulatory milestone in the company's core business strategy to develop seafloor mining operations. While the event is operational and regulatory in nature rather than fitting a specific named category (not M&A, not a contract, not a product launch), it is clearly material to investors as it advances the company's primary development pathway and involves substantial resource potential (1.02 billion tonnes of polymetallic nodules estimated in the USA-B area).
View raw filing on EDGAR →
6-K
Financial Other
confidence 75%
filed 2026-08-17
EX-99.1
Vision Marine completed the sale of its real estate property at 1440 S. Federal Highway in Fort Lauderdale on July 31, 2026, as part of its Florida real estate and operational optimization plan. The transaction monetized a property no longer required under the company's optimized operating footprint and generated proceeds to support capital deployment.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-08-17
EX-99.2
Vision Marine announced authorization of a normal course issuer bid (NCIB) to repurchase up to 326,523 common shares (approximately 5% of outstanding shares) through August 6, 2027. The share repurchase program reflects the company's capital allocation strategy and provides additional financial flexibility following balance sheet strengthening.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-17
EX-99.1
This is a press release announcing Freightos' second quarter 2026 financial results, including record revenue of $7.7 million, gross margin metrics, IFRS loss, Adjusted EBITDA, cash position, and forward-looking guidance for Q3 and full-year 2026. The exhibit contains consolidated balance sheets, statements of operations, and cash flows for the periods ended June 30, 2026, which are characteristic of a quarterly earnings release. Material to investors assessing the company's financial performance and trajectory toward profitability.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-17
EX-99.1
This exhibit is a monthly operational update disclosing bitcoin mining production (46 BTC in July), cryptocurrency treasury holdings (1,917 BTC, 3,952 ETH), hashrate metrics, and mining infrastructure across global operations. While the exhibit also mentions a share repurchase authorization and a Nasdaq Capital Market transfer with a compliance period for minimum bid price, the primary substance is operational—mining output, efficiency metrics, and facility status. The delisting-risk elements (transfer to Nasdaq Capital Market, 180-day compliance period for minimum bid price) are secondary disclosures within a broader operational report and do not constitute the principal event. This is a routine monthly operational disclosure material to investors assessing the company's mining performance and asset position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
Item 2.02
This Item 2.02 disclosure reports United States Antimony Corporation's second quarter 2026 financial and operational results via a conference call held on August 11, 2026. The filing furnishes a transcript of the earnings presentation (Exhibit 99.1) detailing Q2 2026 revenue of $7.9 million (down 25% YoY), gross profit of $0.6 million, operating loss of $7 million, and net income of $0.1 million, along with balance sheet metrics including $41.4 million in cash and $62.2 million in total liquidity. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-17
EX-99.1
This exhibit is a PRC legal opinion issued in connection with YXT.COM GROUP HOLDING LIMITED's offering and sale of 500,000 American depositary shares (representing 15 million Class A ordinary shares) pursuant to a securities purchase agreement dated August 14, 2026. The opinion addresses the enforceability and validity of the transaction documents governing this unregistered equity issuance, which is a classic dilutive issuance event material to investors assessing ownership dilution and capital structure changes.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-17
Item 2.01
AvalonBay Communities, Inc. completed a merger of equals with Equity Residential on August 17, 2026, creating Vivmark Residential (NYSE: VMRK), a combined company with approximately $51 billion equity market capitalization and ~184,000 rental apartments. Each AvalonBay share was converted into 2.793 shares of Vivmark, with AvalonBay shareholders holding approximately 51% of the combined entity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-17
Item 3.01
Following completion of the merger, AvalonBay Common Stock was delisted from the NYSE effective August 17, 2026, with the NYSE filing Form 25 to remove the stock from trading and triggering deregistration under Section 12(b) of the Exchange Act. The successor entity intends to file Form 15 to suspend reporting obligations.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-17
Item 5.02
Upon the effective time of the merger on August 17, 2026, all directors and officers of AvalonBay Communities ceased to hold their positions as AvalonBay ceased to exist and was merged into the surviving entity, with all executive roles replaced by those of the combined Vivmark Residential company.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-17
Item 2.02
The filing discloses a cash distribution to unitholders of $0.027000 per unit payable on September 15, 2026, announced via press release on August 17, 2026. This is a routine monthly distribution announcement for a royalty trust, which constitutes a dividend_distribution event. The disclosure includes underlying production volumes, commodity prices, and cash receipts that support the distribution calculation, making it material to investors in the Trust's units.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-08-17
Item 1.01
UGI Utilities, a wholly owned subsidiary of UGI Corporation, entered into a Note Purchase Agreement on August 11, 2026, for the private placement of $125 million aggregate principal amount of 5.45% Senior Notes maturing August 15, 2031. The agreement was funded on the same date and creates a material direct financial obligation.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-17
Item 2.02
This is a straightforward earnings release disclosing Vuzix's second quarter 2026 financial results for the period ended June 30, 2026. The press release, attached as Exhibit 99.1, presents condensed consolidated statements of operations data, revenue comparisons, expense analysis, net loss per share ($0.09 vs. $0.10 prior year), and cash position ($17.3 million with no debt). The filing is made under Item 2.02 (Results of Operations and Financial Condition), the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-17
Item 1.01
Limoneira entered into a Purchase and Sale Agreement to sell Windfall Farms, a 724-acre vineyard property in Paso Robles, California, for $15 million in an all-cash transaction. The sale is a material disposition of a non-core real estate asset expected to generate significant proceeds to reduce debt and fund strategic initiatives.
View raw filing on EDGAR →
8-K
Material Impairment
confidence 95%
filed 2026-08-17
Item 2.06
Limoneira disclosed an additional impairment charge of approximately $4.1 million in Q4 fiscal 2026 related to the Windfall Farms property sale, bringing the aggregate impairment to approximately $13.4 million on property, plant and equipment assets.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
LiveRamp stockholders voted at a Special Meeting on August 17, 2026, approving seven proposals including a merger agreement with Publicis Groupe (via MMS USA Holdings and Merger Sub), director elections, equity plan amendments, say-on-pay votes, and auditor ratification. The merger proposal received overwhelming approval with 51.6M votes in favor versus 60K against.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-08-17
Item 5.02
Stockholders approved an amendment and restatement of the Company's 2005 Equity Compensation Plan to increase available shares by 2,500,000, a material modification to the equity plan affecting future executive and employee compensation capacity.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-17
The 6-K discloses that MDJM LTD's Class A ordinary shares have been delisted from Nasdaq following a final decision by the Nasdaq Listing and Hearing Review Council on July 28, 2026, affirmed by the Nasdaq Board on August 12, 2026. The Company's shares are now quoted only on the OTCQB Venture Market under ticker "UOKAF." This is a material delisting event that materially affects the registrant's market access and investor base.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-17
Item 1.01
Coherus Oncology entered into a Loan and Security Agreement on August 12, 2026, creating a new senior secured term loan facility of $55 million (Tranche A) with maturity in August 2031. The company drew the full amount on August 14, 2026, using proceeds to repay prior debt and fund working capital, with improved terms (4.15% + greater of Prime/6.75%) compared to the prior facility.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-08-17
Item 1.02
Coherus Oncology terminated its Prior Loan Agreement on August 14, 2026, following full repayment of outstanding amounts and release of all security interests, as part of refinancing into the new senior secured term loan facility.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-17
Item 8.01
Coherus Oncology announced a special dividend distribution of contingent value rights (CVRs) to stockholders on a pro rata basis (one CVR per share), with a record date of September 30, 2026 and distribution on October 7, 2026. The CVRs entitle holders to receive net proceeds from the sale or monetization of the company's legacy biosimilar assets over a two-year term, representing a material capital allocation decision to unlock shareholder value while completing the company's transformation into a focused oncology company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-17
Item 2.02
Prairie Operating Co. announced its financial results for the quarter ended June 30, 2026 via press release on August 17, 2026, disclosing Q2 2026 revenue of $98.9 million (up 45% YoY), net income of $193.8 million, and adjusted EBITDA of $34.0 million. The full press release is attached as Exhibit 99.1 and contains detailed financial statements, production metrics, and forward guidance, which is the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 65%
filed 2026-08-17
Item 2.03
Prairie Operating Co. entered into a Third Amendment to its A&R Credit Agreement that materially modifies existing debt covenants, including reduced Current Ratio requirements and new hydrocarbon production thresholds, along with a Letter Agreement amending warrant issuance terms and waiving certain covenant obligations. These amendments restructure the company's debt relationship and financial obligations.
View raw filing on EDGAR →
8-K
Governance Other
confidence 65%
filed 2026-08-17
Item 3.03
A Letter Agreement materially modifies the rights of security holders, including amendments to warrant issuance terms and conditional waivers of certain covenant obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
This Item 5.07 filing discloses the results of the 2026 Annual Meeting of Stockholders held on August 12, 2026, including voting outcomes for two proposals: (1) election of four directors to one-year terms, with detailed vote tallies for each nominee (Jerome S. Flum, Lisa Reisman, Joshua M. Flum, and Lawrence Fensterstock), and (2) ratification of CohnReznick LLP as independent auditor, with 7,751,920 votes for and 14,945 against. This is a textbook shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-17
Item 1.01
Existing shareholder KKR Genetic Disorder L.P. entered into an Underwriting Agreement for a secondary offering of 5,000,000 shares of common stock at $78.00 per share, with the Company not receiving proceeds but existing shareholders experiencing dilution of ownership percentages.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-08-17
Item 2.01
AvalonBay Communities, Inc. and Equity Residential completed their merger of equals, creating Vivmark Residential (NYSE: VMRK) with approximately $51 billion equity market capitalization, $70 billion enterprise value, and 184,000 rental apartments. The transaction involved a 2.793 exchange ratio, issuance of approximately 400 million common shares, reconstitution of the board with seven directors from each legacy company, appointment of new executive officers, and amendments to the Declaration of Trust and bylaws effective August 17, 2026.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-17
EX-99.1
This is a formal earnings release for Credicorp Ltd.'s second quarter 2026 results, dated August 13, 2026, disclosing consolidated financial and operating results including net income of S/1,981.9 million, ROE of 20.3%, loan growth of 13.1% YoY, and updated medium-term ROE guidance to 22.0%. The document explicitly states "Credicorp Ltd. Reports Financial and Operating Results for 2Q26" and contains detailed financial tables, management commentary, and forward guidance typical of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-17
Item 5.02
Matthew Sobczyk was promoted from Corporate Controller to Interim Chief Financial Officer effective August 14, 2026, succeeding Rashed Dewan who resigned from the CFO position. The appointment addresses the company's financial leadership continuity following the departure of the prior CFO.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-17
EX-99.1
This press release announces a material pipeline expansion and refocus: the addition of EVX-05, a new glioblastoma vaccine program developed in collaboration with Duke University, and the discontinuation of the EVX-03 program. While the company characterizes this as "portfolio management," the launch of a new clinical-stage program targeting a high-mortality cancer with significant unmet medical need, combined with an academic partnership for clinical testing, represents a material operational and strategic shift that would affect a reasonable investor's assessment of the company's R&D direction and competitive positioning.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-17
Item 7.01
Profound Medical announced the introduction of new Treatment Delivery Console (TDC) software for its TULSA-PRO platform, featuring real-time interventional MRI control and user interface improvements designed to increase procedural efficiency from four to potentially six procedures per day. This is a material product enhancement for a commercial-stage medical device company, but does not fit the specific operational categories (workforce reduction, material contract, regulatory milestone). The disclosure is operational and strategic in nature—a significant software upgrade to the company's flagship platform—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-17
Item 8.01
Axe Compute has entered into agreements with Duos Technologies for 55 MW of AI data center capacity representing over $500 million in expected aggregate payments, plus nonbinding term sheets for 49% equity investments in the associated project entities. This is a material strategic partnership and capacity expansion that affects the company's operational footprint and financial commitments, but does not constitute a traditional M&A transaction (no change of control, acquisition, or merger). The event is clearly operational and strategic in nature—a major infrastructure partnership and investment arrangement—making it best classified as an operational event rather than M&A activity.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-17
EX-99.1
TOP Ships has entered into a share purchase agreement to acquire three special purpose vehicles (SPVs), each holding a shipbuilding contract for high-specification MR tankers. The acquisition represents a material capital deployment ($7.4 million net consideration) with significant revenue implications (~$141 million gross revenue backlog from the three vessels alone, bringing total backlog to ~$929 million). The transaction was approved by an independent special committee with a fairness opinion, and closing is expected by September 30, 2026, meeting the definition of material acquisition activity under Item 1.01.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-17
EX-99.1
This press release announces a significant permitting milestone for the South Railroad gold project: receipt of a positive Record of Decision (ROD) from the U.S. Bureau of Land Management, completing federal NEPA permitting. The ROD unlocks early works construction and positions the project for first gold production in 2028, with expected production of 130,000 ounces annually over the first five years and initial capital costs of $395 million. This is a material operational and strategic milestone for the company's organic development pipeline and growth objectives, but does not fit the specific event categories (it is neither a discrete M&A transaction, a financial result, nor a governance or legal event in the traditional sense).
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-17
EX-99.1
This is a press release announcing Rubico Inc.'s financial results for the six months ended June 30, 2026, disclosing a net loss of $1.1 million, revenues of $9.7 million, operating cash flow of $4.1 million, and key balance-sheet metrics. The document explicitly states "announced today its financial results" and references the unaudited interim condensed consolidated financial statements filed on Form 6-K, making this a classic interim earnings release. Material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-17
Gilat announced a $14 million contract with Peru's Regional Government of Ayacucho to deploy fiber-optic broadband infrastructure serving 273 public institutions and ~20,000 residents. This is a material operational/commercial milestone—a significant new contract win for the company's Peruvian subsidiary—but does not fit the specific event categories (not M&A, not a discrete financial obligation like debt issuance, not a restructuring). The contract represents meaningful revenue and strategic expansion of Gilat's digital infrastructure business in Latin America.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-17
Item 8.01
T3 Defense received notice from Nasdaq on August 17, 2026 that it regained compliance with the minimum bid price requirement of $1.00 per share under Listing Rule 5450(a)(1). This disclosure directly addresses a delisting risk: the company had previously failed to maintain the minimum bid price (as disclosed in a May 8, 2026 8-K) and now reports restoration of compliance. The event is material because it resolves a significant threat to the company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-17
Item 8.01
Mosaic announced the expiration and final results of cash tender offers to repurchase four series of outstanding debt securities totaling approximately $1.75 billion in principal amount. While this is technically a debt retirement rather than issuance, the event involves material modification of the company's direct financial obligations and capital structure. The tender offer results—accepting $871 million of the 2027, 2028, and 2029 notes—represent a significant financial transaction that would affect investor assessment of the company's leverage and liquidity position.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-17
Item 7.01
Brandywine's operating partnership has commenced cash tender offers for up to $100 million in aggregate principal amount of outstanding debt securities (7.550% notes due 2028 and 8.875% notes due 2029). While this is technically a debt repurchase rather than new issuance, it represents a material modification of the company's direct financial obligations and capital structure. The company intends to fund the tender offer with cash on hand and/or borrowings under its $600 million credit facility, creating or modifying financial obligations. This is most closely aligned with debt_issuance as it involves material creation or modification of direct financial obligations, though it could alternatively be classified as financial_other given the repurchase nature.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-17
Item 5.02
Matt White was appointed as Chief Financial Officer of Bakkt, Inc., effective August 17, 2026, succeeding Karen Alexander. The appointment includes material compensation terms: base salary of $300,000, 90,000 restricted stock units, 60,000 stock options at a $10.00 exercise price, and severance provisions.
View raw filing on EDGAR →
6-K
Financial Other
confidence 75%
filed 2026-08-17
The 6-K furnishes two related-party asset acquisition announcements (Exhibits 99.1 and 99.2) in which Chunghwa Telecom's subsidiaries (Light Era Development Co., Ltd. and Honghwa International Corporation) acquire right-of-use assets from the parent company. The transactions involve office premises leases totaling approximately NT$10.5 million in right-of-use assets. These are intra-group asset transfers with board approval and audit committee ratification, disclosed under Taiwan's asset acquisition rules. While the transactions are related-party dealings requiring disclosure, they are routine operational leases between parent and subsidiaries rather than discrete material events (M&A, impairment, debt, or earnings). The domain is clearly financial but the specific event type does not fit the named categories; `financial_other` is appropriate for asset acquisitions that do not rise to the level of a major disposition or M&A activity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-08-17
Item 1.01
Fulcrum Therapeutics entered into a definitive Agreement and Plan of Merger with Slate Medicines on August 16, 2026, whereby Slate will merge into Fulcrum's subsidiary with Slate surviving the first merger, followed by a second merger creating a combined entity operating as Slate Medicines. The all-stock transaction represents a fundamental change of control, with Fulcrum stockholders owning approximately 5% and Slate stockholders 95% of the combined entity post-closing, accompanied by a concurrent $245 million private placement financing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-17
Item 3.02
Slate Medicines conducted an oversubscribed concurrent private placement of $245 million in unregistered equity securities exempt under Section 4(a)(2) and Regulation D to healthcare investors, with proceeds to fund the combined company's operations into 2029.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-08-17
Item 1.01
Blue Ridge Bankshares entered into a definitive Agreement and Plan of Merger with HomeTrust Bancshares on August 16, 2026, whereby HomeTrust will acquire Blue Ridge in an all-stock transaction valued at approximately $448.1 million. Blue Ridge shareholders will receive 0.086 shares of HomeTrust common stock per share, with expected closing in early Q1 2027, subject to customary closing conditions including regulatory and shareholder approvals.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-17
Item 8.01
EyePoint announced topline data from LUGANO, a pivotal Phase 3 clinical trial for DURAVYU in wet AMD. While the primary endpoint was not achieved in the full dataset, the company disclosed clinically meaningful secondary endpoint results (42% reduction in treatment burden, 76% supplement-free rates, favorable safety profile) and signaled plans for an NDA filing in 1H 2027 pending results from the second trial (LUCIA) expected in Q4 2026. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the product's regulatory and commercial prospects, but does not fit the earnings_release category (no financial results) or other specific event types.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-08-17
Item 1.01
Galaxy Gaming cancelled 778,320 warrants (approximately 3% of fully diluted shares) for $1.2 million in cash, reducing potential dilution and simplifying the company's capital structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-17
Item 8.01
Virginia Electric & Power Company entered into an underwriting agreement on August 10, 2026 to issue $1.95 billion in aggregate principal amount of Senior Notes ($1.25 billion Series C 5.65% due 2036 and $700 million Series D 6.30% due 2056). This is a material creation of direct financial obligations under a registered offering, clearly fitting the debt_issuance category. The substantial principal amounts and multi-decade maturities make this material to investors.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-08-17
The NYSE has imposed a trading halt on the Company's ADSs following disclosure of a delayed IPO closing. The Company's ADSs began trading on August 12, 2026 on a when-issued basis but the offering has not closed as of the filing date (August 17, 2026) due to unresolved regulatory complaints concerning the controlling shareholders' compliance and restructuring transactions. While the filing does not explicitly state delisting, a trading halt combined with a failed IPO closing and ongoing regulatory issues creates material delisting risk under Item 3.01 standards.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-17
Item 1.01
The filing discloses entry into an Agency Agreement with Piper Sandler for marketing the Company's common stock in connection with a stock offering tied to a two-tier holding company reorganization. The offering is being conducted pursuant to a Form S-1 Registration Statement, indicating a public offering of equity securities. While the Item 1.01 caption references a "material definitive agreement," the substance is a dilutive equity issuance—the Company is raising capital through the sale of common stock to the public, which is material to existing shareholders.
View raw filing on EDGAR →